Last updated: February 15, 2026
Overview
NDC 51672-1264 refers to Lutathera (lutetium Lu 177 dotatate), a radiolabeled peptide used in treating neuroendocrine tumors (NETs). Approved by the FDA in 2018, Lutathera is a targeted radiotherapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is marketed by Advanced Accelerator Applications (a Novartis company).
Market Size and Growth
The NETs market, specifically radiolabeled therapies, has expanded since Lutathera's approval, driven by increasing incidence rates and enhancements in diagnostic screening, leading to earlier detection.
- Global NETs Incidence: Estimated at 6-10 cases per 100,000 annually, with higher prevalence in Europe and North America.
- Lutathera’s Market Penetration: As of 2023, approximately 8,000-10,000 patients worldwide have received Lutathera, primarily in developed markets.
Competitive Landscape
Lutathera's primary competitors include other peptide receptor radionuclide therapy (PRRT) agents, off-label therapies, and diagnostic radioligand imaging.
- Existing Therapies: External beam radiotherapy, chemotherapy, targeted agents like everolimus and sunitinib.
- Emerging Agents: Investigational PRRT options with different isotopes or formulations.
Lutathera's unique FDA approval for specific NETs offers competitive advantage but faces potential competition from generics or biosimilars post-patent expiry, projected around 2030.
Pricing and Reimbursement
Lutathera's pricing varies by region:
- United States: Approximate list price of $26,000 per dose, with a typical course requiring 4 administrations, totaling around $104,000 per patient.
- Europe: Prices range from €20,000 to €30,000 ($22,000-$33,000), depending on country and hospital negotiations.
Reimbursement policies are region-specific. In the U.S., Lutathera is covered largely through Medicare and private insurers, with patients often facing co-pays. In Europe, national health systems often negotiate final prices through reimbursement structures.
Price Projections (2023–2028)
Market growth driven by increasing indication approvals, expanded awareness, and broader geographic access suggests stable price trends in mature markets, with potential slight discounts due to increased competition and biosimilar entries.
| Year |
Expected Market Size (Patients) |
Estimated Price per Course |
Total Revenue Projection |
Comments |
| 2023 |
10,000 |
$104,000 |
$1.04 billion |
Market mature; limited room for price hikes. |
| 2024 |
12,000 |
$102,000 |
$1.22 billion |
Slight volume increase; prices stabilize. |
| 2025 |
14,000 |
$100,000 |
$1.4 billion |
Competition may pressure prices. |
| 2026 |
16,000 |
$98,000 |
$1.57 billion |
Biosimilar entry possible. |
| 2027 |
18,000 |
$97,000 |
$1.75 billion |
Market expansion continues. |
| 2028 |
20,000 |
$95,000 |
$1.9 billion |
Further growth expected; price somewhat reduced. |
Key Market Drivers
- Expanded indications (e.g., pancreatic NETs).
- Increasing adoption and clinical guideline endorsements.
- Continued technological improvements in logistics and administration.
- Potential emergence of biosimilars post-2030 could reduce costs.
Risks
- Regulatory delays or restrictions.
- Development of alternative therapies.
- Pricing constraints due to healthcare budgets.
Regulatory and Patent Outlook
Patent protections commenced at approval in 2018, with exclusivity expected until around 2030. Biosimilar efforts are active, with generic equivalents possibly entering the late 2020s, which may impact pricing.
Conclusion
Lutathera’s global market is expected to grow at a CAGR of approximately 10-12% until 2028, with prices remaining relatively stable until increased competition influences downward pressure. Market expansion hinges on broader approvals, improved access, and clinical acceptance.
Key Takeaways
- The current U.S. list price per course is approximately $104,000.
- Market size projected to increase from 10,000 to 20,000 patients globally by 2028.
- Price stability expected until biosimilars enter circulation, likely after 2028.
- Revenue growth driven by increased indications, geographic expansion, and adoption.
- Price competition may intensify with biosimilar entries and healthcare cost containment.
FAQs
1. When does Lutathera patent expiration occur?
Expected around 2030, allowing biosimilar development and market entry.
2. How does Lutathera compare price-wise with similar therapies?
It is priced higher than standard chemotherapies but competitive within targeted radiotherapies. Pricing varies significantly globally.
3. What factors influence Lutathera's market growth?
Indication expansion, increased clinical adoption, improved reimbursement policies, and geographic market penetration.
4. Are biosimilars likely to affect Lutathera's pricing?
Yes, biosimilar development could lead to price reductions post-2028.
5. How does regulatory approval influence price projections?
Approval in additional indications or markets can increase demand and revenue, maintaining or increasing prices until biosimilar competition emerges.
References
- FDA. (2018). FDA approves Lutathera for certain gastrointestinal cancers.
- Novartis. (2023). Lutathera prescribing information.
- IQVIA. (2023). Global oncology radiopharmaceutical market data.
- European Medicines Agency. (2022). Review of Lutathera approvals.
- MMV. (2023). Pharmacoeconomic assessments of PRRT agents.
